Eugene R. Viscusi, MDAnesthesiologist and pain specialist
Learn about Dr. Viscusi's clinical use of OFIRMEV and link to more HCPs to hear their experiences
Anthony Gonzalez, MDBariatric surgeonChief of Surgery at Baptist Hospital of Miami
Learn about Dr. Gonzalez's clinical use of OFIRMEV and link to more HCPs to hear their experiences
Take a closer look at the clinical data fromPain Study 1.
Read more...
Sinatra et al (Pain Study 1) Randomized, double-blind, placebo-controlled, single- and repeated-dose 24-h study (n=101). Patients received OFIRMEV 1 g + PCA morphine or placebo + PCA morphine the morning following total hip or knee replacement surgery. Primary endpoint: pain relief measured on a 5-point verbal scale over 6 h. Morphine rescue was administered as needed. P<0.05 at every time point.
See how OFIRMEV + PCA morphine significantly reduced morphine consumption vs placebo + PCA morphine1
Sinatra et al (Pain Study 1) Randomized, double-blind, placebo-controlled, single- and repeated-dose 24-h study (n=101). Patients received OFIRMEV 1 g + PCA morphine or placebo + PCA morphine the morning following total hip or knee replacement surgery. Primary endpoint: pain relief measured on a 5-point verbal scale over 6 h. Morphine rescue was administered as needed.